Doxorubicin Cytotoxicity Assay with ALDH Inhibitor

The cytotoxicity of doxorubicin (MP Biomedicals, Solon, OH), either alone or in
combination with the ALDH inhibitor DEAB, was determined by methylthiazol
tetrazolium (MTT) assays (Sigma-Aldrich).^{3 (link)} The inhibitory concentration 50 (IC₅₀) was calculated using
GraphPad Prism version 6.0 for Mac OS X statistics software (GraphPad Software,
San Diego, CA).

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Lasso P., Llano Murcia M., Sandoval T.A., Urueña C., Barreto A, & Fiorentino S. (2019). Breast Tumor Cells Highly Resistant to Drugs Are Controlled Only by the Immune Response Induced in an Immunocompetent Mouse Model. Integrative Cancer Therapies, 18, 1534735419848047.

Publication 2019

doxorubicin MTT) assays Mac OS X

Assays Cytotoxicity Deab Doxorubicin Prism Solon

Corresponding Organization : Pontificia Universidad Javeriana

Top 5 similar protocols

Variable analysis

independent variables

Doxorubicin (MP Biomedicals, Solon, OH)
ALDH inhibitor DEAB

dependent variables

Cytotoxicity

control variables

Not explicitly mentioned

controls

Not specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!